Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
AFT Pharmaceuticals (AFT NZ)
Watchlist
47
Analysis
Health Care
•
New Zealand
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products. The Company offers medicines for allergy, cough, cold, and flu, eye care, pain management, and laxatives. AFT Pharmaceuticals serves customers worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
AFT Pharmaceuticals
•
24 May 2024 05:29
•
Broker
AFT Pharmaceuticals - FY24 Result — Roaring Revenue
We retain our OUTPERFORM rating with an unchanged target price of NZ$4.60 (roll forward and peers re-rate offsets earnings downgrades).
Forsyth Barr
Follow
246 Views
Share
bearish
•
AFT Pharmaceuticals
•
19 Feb 2024 08:37
•
Broker
AFT Pharmaceuticals - A Bumpy Road
While it stated this was due to weaker-than-expected Australasian sales, relative to our expectations it was gross margins remaining soft.
Forsyth Barr
Follow
178 Views
Share
bullish
•
AFT Pharmaceuticals
•
24 Nov 2023 07:26
•
Broker
AFT Pharmaceuticals - 1H24 Result — Not Without Some Pain
The key positive was underlying non-ANZ sales growth of +95% versus 1H23, which, coupled with ongoing solid ANZ performance, more than offset gross...
Forsyth Barr
Follow
366 Views
Share
bullish
•
AFT Pharmaceuticals
•
18 Oct 2023 08:37
•
Broker
AFT Pharmaceuticals - FDA Pain Is Over
AFT Pharmaceuticals (AFT) has finally received the long awaited US FDA approval for its Maxigesic IV product (hospital-based product)
Forsyth Barr
Follow
352 Views
Share
bullish
•
AFT Pharmaceuticals
•
03 Jun 2023 20:00
•
Broker
AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
Forsyth Barr
Follow
345 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.7
x